HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz emphasized Bio-Rad's ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving ...

ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...

It's been a good week for Bio-Rad Laboratories, Inc. (NYSE:BIO) shareholders, because the company has just released its latest quarterly results, and the shares gained 7.7% to US$285. The results were ...

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...

Testifying in a retaliation trial pitting a fired attorney against his former employer Bio-Rad Laboratories, the company’s CFO said Tuesday the attorney’s erratic behavior included an incident that ...

Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro ...

BIO is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of BIO shares has decreased $5.90 since the market last closed. This is a 1.92% ...